Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Sponsor
Seung Up Kim
Study ID
NCT05473806
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Pioglitazone 15 Mg Oral Tablet — DRUG
    24weeks dose
  • Evogliptin 5mg — DRUG
    24weeks dose

Study Details

An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis

Key Dates

First listed
Jul 26, 2022
Start date
Sep 18, 2020
Status verified
Jul 2022
Primary completion
Jan 19, 2023
Completion
Feb 19, 2023

Study Design

Enrollment
28 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Pioglitazone 15mg
    pioglitazone hydrochloride. PO. 2 tablets once a day.
  • Experimental: Evogliptin 5mg
    Evogliptin tartrate. PO. 1 tablets once a day.

Primary Outcome Measure

Changes in Liver Stiffness Measurement at 24 weeks compared to baseline. [ Time Frame: 24 weeks ]

Related Studies